Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Neoplasms AND Extensive Stage Small Cell Lung Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    67 result(s) found for: Neoplasms AND Extensive Stage Small Cell Lung Cancer. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2015-001097-18 Sponsor Protocol Number: CA209-331 Start Date*: 2015-09-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy
    Medical condition: Relapsed Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) GR (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004091-18 Sponsor Protocol Number: D6132C00001 Start Date*: 2021-09-13
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Ba...
    Medical condition: First-line patients with extensive disease small-cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-006134-17 Sponsor Protocol Number: IPM3002 Start Date*: 2012-07-30
    Sponsor Name:ZIOPHARM Oncology, Inc.
    Full Title: A Multi-center, Open-Label, Adaptive, Randomized Study of Palifosfamide-tris, a Novel DNA Crosslinker, in Combination with Carboplatin and Etoposide (PaCE) Chemotherapy versus Carboplatin and Etopo...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) PL (Completed) IT (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003795-49 Sponsor Protocol Number: IFCT-1603 Start Date*: 2016-12-16
    Sponsor Name:IFCT
    Full Title: A randomized multicenter, open label, controlled and non-comparative phase II study of anti–PDL1 ATEZOLIZUMAB (MPDL3280A) or chemotherapy as second-line therapy in patients with small cell lung can...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-003301-97 Sponsor Protocol Number: GO41767 Start Date*: 2020-04-15
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE...
    Medical condition: Small cell lung cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) HU (Completed) BE (Completed) ES (Ongoing) GR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001822-31 Sponsor Protocol Number: ESR_21-21396 Start Date*: 2023-06-16
    Sponsor Name:Saarland University represented by the Vice President for Research, Prof. Dr. med. Veit Flockerzi
    Full Title: Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)
    Medical condition: Patients with oligometastatic extensive stage small cell lung carcinoma (ES-SCLC). In this trial oligometastatic disease is defined as up to five tumor lesions.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001764-35 Sponsor Protocol Number: M14-361 Start Date*: 2014-12-04
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lun...
    Medical condition: Extensive Stage Disease Small Cell Lung Cancer (ED SCLC)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed) CZ (Completed) BE (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-003031-29 Sponsor Protocol Number: D4191C00137 Start Date*: 2022-04-07
    Sponsor Name:AstraZeneca AB
    Full Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study with Durvalumab and Are Judged by the Investigator to Clinically Benefit From Continued Treatment
    Medical condition: Post-Chemotherapy Urothelial and Non-Urothelial Carcinoma of the Urinary Tract. First-line patients with extensive disease (Stage IV) small-cell lung cancer (SCLC). Advanced or Metastatic Non Small...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061272 Malignant urinary tract neoplasm PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025055 Lung cancer non-small cell stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001692-67 Sponsor Protocol Number: CA001-044 Start Date*: 2016-09-27
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Randomized Trial of BMS-986012 in Combination with Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2013-003503-19 Sponsor Protocol Number: MGN1703-C03 Start Date*: 2014-01-28
    Sponsor Name:Mologen AG
    Full Title: Randomized Clinical Trial of Maintenance Therapy with Immunomodulator MGN1703 in Patients with Extensive Disease Small Cell Lung Cancer after Platinum-Based First-Line Therapy
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-001648-91 Sponsor Protocol Number: TRIPLEX Start Date*: 2021-09-21
    Sponsor Name:Norwegian University of Science and Technology
    Full Title: Randomized phase III trial investigating the survival benefit of adding thoracic radiotherapy to durvalumab (MEDI4736) immunotherapy plus chemotherapy in extensive stage small-cell lung cancer
    Medical condition: Extensive stage small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) EE (Trial now transitioned) NL (Trial now transitioned) IS (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002497-37 Sponsor Protocol Number: IOV-SCLC-1-2014-TIMES Start Date*: 2014-12-22
    Sponsor Name:Istituto Oncologico del Veneto IRCCS – UOC Oncologia Medica 2
    Full Title: TIvantinib as Maintenance treatment in Extended Small-cell lung cancer (TIMES) Phase II clinical trial, single arm, two stage
    Medical condition: Small Cell Lung Cancer (SCLC) after first-line platinum plus etoposide therapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004155-39 Sponsor Protocol Number: BAY1000394/14858 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer Healthcare AG
    Full Title: Phase Ib / II study of BAY 1000394 in combination with cisplatin / etoposide or carboplatin / etoposide as first-line therapy in subjects with extensive disease small cell lung cancer
    Medical condition: Subjects with histologically or cytologically confirmed, extensive disease SCLC without prior systemic antitumor therapy are eligible. Subjects should have evaluable or measurable disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001707-21 Sponsor Protocol Number: AIO-TRK-0119 Start Date*: 2019-12-05
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Single-Arm Phase II-Study in Patients with extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status receiving Atezolizumab-Carboplatin-Etoposide
    Medical condition: treatment-naive, extensive stage small-cell lung cancer (ES-SCLC) with Poor Performance Status with or without asymptomatic brain metastases (stage IV, ECOG=2)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001679-31 Sponsor Protocol Number: GEM017 Start Date*: 2009-02-05
    Sponsor Name:Cephalon, Inc.
    Full Title: A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclax Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Medical condition: Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) GB (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-001863-10 Sponsor Protocol Number: CA001-050 Start Date*: 2021-04-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
    Medical condition: Extensive-stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001256-39 Sponsor Protocol Number: CA184-041 Start Date*: 2008-02-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of Ipilimumab (BMS-734016) in Combination with Taxol®/Paraplatin® (Paclitaxel/Carbopl...
    Medical condition: Study Population: Men and women who are ≥ 18 years old with histologically or cytologically confirmed lung cancer (Stage IIIb/IV NSCLC or extensive stage SCLC) with ECOG performance ≤ 1, who have m...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029521 Non-small cell lung cancer stage IIIB PT
    9.1 10029522 Non-small cell lung cancer stage IV PT
    9.1 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003063-21 Sponsor Protocol Number: HLX10-005-SCLC301 Start Date*: 2020-06-17
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Randomized, Double-Blind, Multicenter, Phase III Study to Compare Clinical Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) in Combination with Chemoth...
    Medical condition: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-001114-19 Sponsor Protocol Number: IB2022-01 Start Date*: 2023-04-03
    Sponsor Name:Institut Bergonié
    Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer
    Medical condition: platinum sensitive extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-001146-17 Sponsor Protocol Number: ML41118 Start Date*: 2019-07-16
    Sponsor Name:ROCHE SPA
    Full Title: A PHASE IIIB, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) IN COMBINATION WITH CARBOPLATIN PLUS ETOPOSIDE TO INVESTIGATE SAFETY AND EFFICACY IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE ...
    Medical condition: EXTENSIVE-STAGE SMALL CELL LUNG CANCER (es-SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 06:44:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA